Cullen/Frost Bankers
MYGN icon

Cullen/Frost Bankers’s Myriad Genetics MYGN Stock Holding History

Cullen/Frost Bankers’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28K Buy
+4,910
New +$22.3K ﹤0.01% 998
2024
Q3 		– Sell
-74
Closed -$1.81K – 1321
2024
Q2 		$1.81K Hold
74
– – ﹤0.01% 1122
2024
Q1 		$1.58K Hold
74
– – ﹤0.01% 955
2023
Q4 		$1.42K Hold
74
– – ﹤0.01% 971
2023
Q3 		$1.19K Hold
74
– – ﹤0.01% 1101
2023
Q2 		$1.72K Buy
+74
New +$1.61K ﹤0.01% 1058
2021
Q4 		– Sell
-856
Closed -$28K – 1277
2021
Q3 		$28K Hold
856
– – ﹤0.01% 902
2021
Q2 		$26K Buy
+856
New +$24.7K ﹤0.01% 933

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cullen/Frost Bankers's MYGN Position: Q2 2026 in Review

Cullen/Frost Bankers opened a new position in Myriad Genetics (MYGN) in Q2 2026: 4,910 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #998 among its holdings. This is a return to the name: Cullen/Frost Bankers previously reported a position in MYGN as recently as Q2 2024.

Cullen/Frost Bankers first reported a position in MYGN in Q2 2021 and has held it in 8 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Cullen/Frost Bankers held 4,910 shares of Myriad Genetics worth $28K as of Q2 2026.
  • Myriad Genetics was a new Cullen/Frost Bankers position in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #998 holding.
  • Cullen/Frost Bankers first reported a position in Myriad Genetics in Q2 2021 and has held it in 8 quarters since.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.